Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixinity in Severe Hemophilia B
NCT02048111Phase 3Withdrawn
- Sponsor
- Cangene Corporation
- Start
- Mar 2014
- Primary completion
- Oct 2015
- Countries
- 2
01
Overview
A Phase 3 trial of trenonacog alfa in hemophilia B (HB), sponsored by Cangene Corporation. Planned start Mar 2014; status: withdrawn.
02
Drugs
trenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT02048111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048111.